Advench Pharmaceutical Private Limited

Menveo is a quadrivalent meningococcal conjugate vaccine developed to provide active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y. It is widely used to protect individuals, particularly adolescents, young adults, and those at increased risk due to travel, outbreaks, or underlying health conditions. The vaccine contains oligosaccharides from the four meningococcal serogroups conjugated to CRM197, a non-toxic variant of diphtheria toxin, which enhances immune response and immunological memory. Menveo is indicated for children from 2 years of age through adulthood and is administered as an intramuscular injection. The vaccine has demonstrated strong immunogenicity, high efficacy, and a favorable safety profile in clinical trials and global immunization programs. Common side effects are generally mild and temporary, including injection-site pain, headache, muscle pain, and mild fever. Menveo is recommended by health authorities for routine immunization, pre-travel vaccination to endemic regions, and outbreak control. It must be stored under proper cold-chain conditions (2–8 °C) and protected from freezing. Supplied in convenient vials, Menveo is trusted worldwide to reduce the incidence of life-threatening meningococcal infections.